We report the outcome of patients included in the LNH-98.5 study, which compared
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-…

Since the publication of the Revised European-American Classification of Lymphoid Neoplasms
in 1994, subsequent updates of the classification of lymphoid neoplasms have been …

Acquired genomic aberrations have been shown to significantly impact survival in several
hematologic malignancies. We analyzed the prognostic value of the most frequent …

Background Patient outcomes are poor for aggressive B-cell non-Hodgkin’s lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …

Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …

The clinical activity of rituximab, a chimeric monoclonal antibody which binds to the CD20
antigen, was evaluated as a single first-line therapy for patients with follicular non-Hodgkin …

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). …

High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line
chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study (ClinicalTrials.gov …

Mucosa-associated lymphoid tissue–derived lymphoma (MALT lymphoma) is usually a very
indolent lymphoma, described as localized at diagnosis and remaining localized for a …

PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging,
bispecific antibody that activates T cells, directing them to kill malignant CD20 + B cells. Single-…